Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667033 | 0.83 | MEN1 (0.52) | KMT2AMEN1MAPTCRHBPCRHR2 | |
| SCHEMBL2171507 | 0.83 | KDM4E (0.43) | KMT2AMEN1MAPTALDH1A1GAA | |
| SCHEMBL12448302 | 0.79 | ALDH1A1 (0.52) | KMT2AMEN1MAPTCRHBPCRHR2 | |
| SCHEMBL12838161 | 0.79 | KMT2A (0.49) | KMT2AMEN1MAPTCRHBPCRHR2 | |
| SCHEMBL7447967 | 0.78 | MEN1 (0.52) | KMT2AMEN1MAPTCRHBPCRHR2 | |
| SCHEMBL6681877 | 0.77 | GNRHR (0.49) | KMT2AMEN1MAPTCRHBPCRHR2 | |
| SCHEMBL2172382 | 0.76 | HTT (0.50) | KMT2AMEN1MAPTCRHBPCRHR2 | |
| SCHEMBL1531279 | 0.76 | HTT (0.53) | KMT2AMEN1MAPTPKMHTT | |
| SCHEMBL1669861 | 0.75 | ALDH1A1 (0.47) | KMT2AMEN1MAPTCRHBPCRHR2 | |
| SCHEMBL2172599 | 0.75 | TTR (0.51) | KMT2AMEN1MAPTCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346872-B1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2346872-B1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8754211-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754211-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754211-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-30 | — | — | US | disclosed |
| US-8580959-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580959-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580959-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2011-09-08 | — | — | US | disclosed |
| EP-2346872-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010042682-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042682-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | KMT2A 891/4885MEN1 551/4885MAPT 2645/4885 |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | KMT2A 891/4885MEN1 551/4885MAPT 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.